Differential diagnosis of unconjugated hyperbilirubinemiadetected after coronary artery stenting

Introduction. An increase in bilirubin and liver enzyme activity may be one of the side effects of statin therapy, often occurring in patients after AMI and coronary artery stenting, or in high and very high risk individuals on high and moderate intensity statin therapy. The frequency of occurrence of increased transaminases and bilirubin is according to different authors. Therefore, in terms of differential diagnosis, the cardiologist should consider Gilbert’s syndrome as a possible cause of hyperbilirubinemia. Description of the clinical case. The article considers a clinical case of differential diagnosis of non-conjugated hyperbilirubinemia detected in a patient after coronary artery stenting. The level of hemoglobin, erythrocytes, reticulocytes did not differ from normal values and did not change over time. This made it possible to exclude the hemolytic genesis of hyperbilirubinemia. Genetic testing was used to establish the homozygous form of Gilbert’s syndrome. However, the presence of fibrotic changes in the liver, an increase in not only unconjugated, but also conjugated bilirubin, hypertriglyceridemia, dyslipidemia, and stenosing atherosclerosis of the coronary arteries did not allow us to state that the patient had only Gilbert’s syndrome. Discussion. According to recent studies, this disease is characterized by a benign course and reduces the risk of developing cardiovascular diseases due to the antioxidant effect of bilirubin. In addition to Gilbert’s syndrome, the patient was diagnosed with an erased form of non-alcoholic fatty liver disease associated with metabolic syndrome. Conclusion. The disease was caused by insulin resistance, a high-calorie diet, excess consumption of saturated fats, refined carbohydrates, and a sedentary lifestyle. The drugs of choice in this case are statins, ezetemibe, and ursodeoxycholic acid. Their appointment allows not only to reduce cardiovascular risk, but also to slow down the further progression of liver fibrosis.

Gilbert’s syndrome, non-alcoholic fatty liver disease, unconjugated hyperbilirubinemia, liver fibrosis, statins

1. Gilbert A, Lereboullet P. La cholémie simple familial [A simple family cholehemia]. Semaine médicale. 1901;21:241-243. (in French).

2. Dubrovina G.M., Botvinev O. K., Kolotilina A. I.Combination of Gilbert syndrome with diseases of the gastrointestinal tract.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;24:3:13-21. (in Russ.)@@ Дубровина Г. М., Ботвиньев О. К., Колотилина А. И. Сочетание синдрома Жильбера с заболеваниями желудочно-кишечного тракта. Российский журнал гастроэнтерологии, гепатологии, колопроктологии 2014;24(3):13-21.

3. Volkov A.N., Tsurkan E. V. UGT1A1 gene mutation as a marker indicating there is a high risk of Gilbert’s syndrome: theoretical and applied aspects. Health Risk Analysis. 2019, no. 2, pp. 123-129. (in Russ.) doi: 10.21668/health.risk/2019.2.14.eng.@@ Волков А. Н., Цуркан Е. В. Мутация гена UGT1A1 как маркер высокого риска возникновения синдрома Жильбера: научно-прикладные аспекты. Анализ риска здоровью. 2019;2:123-127. doi: 10.21668/health.risk/2019.2.14.eng.

4. Rasool A., Sabir S., Ashlaq M., Farooq U., Khan M. Z., Khan F. Y. Gilbert’s syndrome - a concealed adversity for physicians and surgeons. J Ayub Med Coll Abbottabad. 2015 Jul-Sep;27(3):707-10. PMID: 26721045.

5. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) 2018 ESC/ESH Guidelines for the management of arterial hypertension.Russian Journal of Cardiology. 2018;(12):143-228. (In Russ.) doi: 10.15829/1560-4071-2018-12-143-228.@@ Рабочая группа по лечению артериальной гипертензии Европейского общества кардиологов (ЕОК, ESC) и Европейского общества по артериальной гипертензии (ЕОАГ, ESH) 2018 ЕОК/ЕОАГ Рекомендации по лечению больных с артериальной гипертензией. Российский кардиологический журнал. 2018;(12):143-228. doi: 10.15829/1560-4071-2018-12-143-228.

6. Fargo MV, Grogan SP, Saguil A. Evaluation of Jaundice in Adults. Am Fam Physician. 2017;1;95(3):164-168. PMID: 28145671.

7. Dugum M, McCullough A. Diagnosis and Management of Alcoholic Liver Disease. J Clin Transl Hepatol. 2015;28;3(2):109-16. doi: 10.14218/JCTH.2015.00008.

8. Bulmer AC, Verkade HJ, Wagner KH. Bilirubin and beyond: a review of lipid status in Gilbert’s syndrome and its relevance to cardiovascular disease protection. Prog Lipid Res. 2013;52(2):193-205. doi: 10.1016/j.plipres.2012.11.001.

9. Louvet A, Mathurin P. Alcoholic liver disease: mechanisms of injury and targeted treatment. Nat Rev Gastroenterol Hepatol. 2015;12(4):231-42. doi: 10.1038/nrgastro.2015.35.

10. Mehta AJ. Alcoholism and critical illness: A review. World J Crit Care Med. 2016;4;5(1):27-35. doi: 10.5492/wjccm.v5.i1.27.

11. Lazebnik L.B., Golovanova E. V., Turkina S. V., et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroenterology. 2021;1(1):4-52. (In Russ.) doi: 10.31146/1682-8658-ecg-185-1-4-52.@@ Лазебник Л. Б., Голованова Е. В., Туркина С. В. и др. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021;1(1):4-52. doi: 10.31146/1682-8658-ecg-185-1-4-52.

12. Mueller S, Seitz HK, Rausch V. Non-invasive diagnosis of alcoholic liver disease. World J Gastroenterol. 2014;28;20(40):14626-41. doi: 10.3748/wjg.v20.i40.14626.

13. Suh S, Cho YR, Park MK, Kim DK, Cho NH, Lee MK. Relationship between serum bilirubin levels and cardiovascular disease. PLoS One. 2018;15;13(2): e0193041. doi: 10.1371/journal.pone.0193041.

14. Moon JS. Role of Bilirubin in Diabetic Vascular Complications: Can Bilirubin Predict More than Just Liver Disease? Diabetes Metab J. 2015;39(5):384-6. doi: 10.4093/dmj.2015.39.5.384.

15. Chan K.H., O’Connell R.L., Sullivan D. R., Hoffmann LS, Rajamani K, Whiting M, Donoghoe MW, Vanhala M, Hamer A, Yu B, Stocker R, Ng MK, Keech AC; FIELD Study Investigators. Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia. 2013;56(4):724-36. doi: 10.1007/s00125-012-2818-4.

16. Horsfall L.J., Nazareth I., Petersen I. Cardiovascular events as a function of serum bilirubin levels in a large, statin-treated cohort. Circulation. 2012 Nov 27;126(22):2556-64. doi: 10.1161/CIRCULATIONAHA.112.114066.

17. Cheriyath P, Gorrepati VS, Peters I, Nookala V, Murphy ME, Srouji N, Fischman D. High Total Bilirubin as a Protective Factor for Diabetes Mellitus: An Analysis of NHANES Data From 1999-2006. J Clin Med Res. 2010 Oct 11;2(5):201-6. doi: 10.4021/jocmr425w.

18. Kumar, Ramesh & Jain, Ritika. Studies on serum nitric oxide levels in subjects with high bilirubin value in comparison of normal healthy control subjects.International Journal of Bioassays. 2016;5. 4870-4875. doi: 10.21746/ijbio.2016.03.004.

19. Drapkina O.M., Korneeva O. N. Continuum of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk. Rational Pharmacotherapy in Cardiology. 2016;12(4):424-429. (In Russ.) doi: 10.20996/1819-6446-2016-12-4-424-429.@@ Драпкина О. М., Корнеева О. Н. Континуум неалкогольной жировой болезни печени: от стеатоза печени до сердечно-сосудистого риска. Рациональная фармакотерапия в кардиологии. 2016;12(4):424-429. doi: 10.20996/1819-6446-2016-12-4-424-429.

20. Nedogoda SV, Chumachek EV, Ledyaeva AA, Tsoma VV, Vlasov DS, Bychkova OI. Non-fixed combination perindopril+moxonidine for blood pressure control in hypertensive patients with metabolic syndrome. Kardiologiya i Serdechno-Sosudistaya Khirurgiya. 2021;14(2):208-214. (In Russ.) doi: 10.17116/kardio202114021208.

21. Younossi Z.M., Stepanova M., Negro F., Hallaji S., Younossi Y., Lam B., Srishord M. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore). 2012 Nov;91(6):319-327. doi: 10.1097/MD.0b013e3182779d49.

22. Ivashkin V.T., Mayevskaya M. V., Pavlov C. S., Tikhonov I. N., Shirokova Y. N., Buyeverov A. O., Drapkina O. M., Shulpekova Yu.O., Tsukanov V. V., Mammayev S. N., Mayev I. V., Palgova L. K. Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientific Liver Society and the Russian gastroenterological association.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(2):24-42. (In Russ.) doi: 10.22416/1382-4376-2016-26-2-24-42.@@ Ивашкин В. Т. и др. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(2):24-42. doi: 10.22416/1382-4376-2016-26-2-24-42.

23. Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013 May 10;5(5):1544-60. doi: 10.3390/nu5051544.

24. Gómez-Ambrosi J, Silva C, Galofré JC, Escalada J, Santos S, Millán D, Vila N, Ibañez P, Gil MJ, Valentí V, Rotellar F, Ramírez B, Salvador J, Frühbeck G. Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity.Int J Obes (Lond). 2012 Feb;36(2):286-94. doi: 10.1038/ijo.2011.100.

25. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004.

26. Barrera F, George J. The role of diet and nutritional intervention for the management of patients with NAFLD. Clin Liver Dis. 2014 Feb;18(1):91-112. doi: 10.1016/j.cld.2013.09.009.

27. Gerber L, Otgonsuren M, Mishra A, Escheik C, Birerdinc A, Stepanova M, Younossi ZM. Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study. Aliment Pharmacol Ther. 2012 Oct;36(8):772-81. doi: 10.1111/apt.12038.